News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Data on UCB, Inc. (UCBJF.PK) Cimzia® (certolizumab pegol) to be Presented at American College of Gastroenterology Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn’s Disease


10/31/2011 9:11:56 AM

ATLANTA--(BUSINESS WIRE)--UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, will present new data on Cimzia® (certolizumab pegol) at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place in Washington D.C. from October 28 to November 2.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES